Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Admedus Ltd to drive growth with market expansion of CardioCel® sales

The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.
Admedus Ltd to drive growth with market expansion of CardioCel® sales
Admedus has received approval for CardioCel® in the UAE.

Admedus Ltd (ASX:AHZ), in collaboration with its regional partner Genpharm, has received market approval for CardioCel® in the United Arab Emirates (UAE) and first orders.

The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.

UAE is an important regional centre for healthcare and cardiovascular disease treatment and the market entry follows on from the recent approval of the product in Kuwait.

Together Admedus and Genpharm will continue to seek additional approvals in the region along with growing sales.

Wayne Paterson, interim CEO, commented: “As we continue to drive strong sales growth of CardioCel®, this approval is a significant milestone in terms of our expansion of the product franchise across emerging markets.

“The UAE is a strategically important location as a central hub in Middle East and North Africa for performing cardiovascular surgery.”


Background

Admedus holds assets from research and development, through clinical development as well as sales, marketing and distribution.

Its flagship product is CardioCel, which is becoming a surgeon-preferred biomaterial for heart valve repair surgeries.

CardioCel represents a disruptive technology in the $2.5 billion heart valve repair and replacement market, which is dominated by products commercialized by large medical device companies.

It is now being sold in Canada, Australia, Asia, the Middle East, and North Africa, covering 135 medical centres.

Admedus also recently received FDA 510(k) clearance to market its vascular product, VascuCel in the U.S.

Furthermore, the Admedus infusion portfolio has over 800 customers providing hospital-wide infusion solutions across the Australian and New Zealand healthcare systems.

Beyond CardioCel and infusion sales, Admedus is developing a DNA-based therapeutic vaccine for HSV-2 and HPV.


Analysis

The geographical expansion of CardioCel markets provides Admedus with an opportunity to increase product sales and brand recognition.

This will support the continued growth of the company, most recently exemplified by the September quarter revenue of $6.05 million, which was up 50% on the previous June quarter.

The UAE has over 500 cases of congenital defects per annum and an increasing number of older patients with congenital defects seeking repair.

Furthermore, Admedus recently launched VascuCel in the U.S. and generated initial sales for the product.

Admedus believes VascuCel will take significant market share in the U.S. vascular market – the global vascular repair market is estimated at $500 million.

The company is also attending the VEITH Symposium this week in New York which is focused on vascular surgery.

Admedus had a healthy cash balance of $19.5 million at the end of the September quarter.

View full AHZ profile View Profile

Admedus Ltd Timeline

Related Articles

scientist looking through a microscope
October 31 2017
As of March, ReNeuron had £53mln in cash equivalents but its market value is not too much above that....
1524140870_ampoules.jpg
April 19 2018
US food and drug administration approval isn't there yet, but Motif continues to chug forwards
pipette and petri dish
Tue
As well as developing its lead compound, Silence has also been busy taking its larger rivals to court over alleged patent infringements

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use